Strategic objectives
European platform advancing RAS-focused cancer research
To address the complexity of RAS-driven cancers, we have defined four strategic pillars designed to integrate basic science with clinical practice and consolidate European leadership in the field.
Establish a Translational - Clinical Loop
Accelerate bench-to-bedside translation by integrating preclinical RAS models with academic clinical trials; simultaneously channel patient-derived data and hypotheses back to refine RAS preclinical research across Europe.
Federate RAS Research Across Europe
Establish a coordinated European network of leading RAS research groups, catalysing joint research, data sharing, and transatlantic collaboration with the NIH–NCI RAS Initiative.
Optimize Shared Resources:
Centralize access to patient-derived materials, reagents, and high-throughput platforms to reduce duplication, lower costs, and enhance efficiency for RAS-targeting studies continent-wide.
Promote Early-Career Scientists
Mentor and support emerging RAS researchers through training programs, symposia, and funding opportunities, building the next generation of European leaders in the field.
Integrating patient perspective
Engaging patients and patient advocates in the definition of research priorities, collaborative initiatives, and dissemination activities, ensuring that the network’s scientific agenda remains aligned with patient needs, perspectives and expectations.